Stemline Therapeutics (NASDAQ: STML) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.


This table compares Stemline Therapeutics and Mersana Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stemline Therapeutics -4,689.63% -75.50% -64.20%
Mersana Therapeutics N/A N/A N/A

Institutional and Insider Ownership

50.2% of Stemline Therapeutics shares are owned by institutional investors. Comparatively, 76.7% of Mersana Therapeutics shares are owned by institutional investors. 16.7% of Stemline Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Stemline Therapeutics and Mersana Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stemline Therapeutics 0 0 5 0 3.00
Mersana Therapeutics 0 0 4 0 3.00

Stemline Therapeutics presently has a consensus target price of $33.75, suggesting a potential upside of 139.36%. Mersana Therapeutics has a consensus target price of $23.67, suggesting a potential upside of 53.28%. Given Stemline Therapeutics’ higher probable upside, equities research analysts plainly believe Stemline Therapeutics is more favorable than Mersana Therapeutics.

Earnings and Valuation

This table compares Stemline Therapeutics and Mersana Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Stemline Therapeutics $1.04 million 342.87 -$38.30 million ($2.57) -5.49
Mersana Therapeutics N/A N/A N/A ($1.03) -14.99

Mersana Therapeutics has lower revenue, but higher earnings than Stemline Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Stemline Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with's FREE daily email newsletter.